Bpifrance innovation project aid: grant or repayable advance

A Bpifrance funding offer rarely comes in a single form. The agreement (convention d'aide) often combines a grant component, a recoverable advance and sometimes a zero-rate loan, each with its own rules on repayment, accounting and impact on the research tax credit. Before signing, the right question is therefore not "how much will Bpifrance fund?", but "what will I have to repay, when, and what happens to my balance sheet and my research tax credit if the project fails?".

Quick answer. Bpifrance innovation project aid takes three forms in 2026: the grant (up to 50% of eligible expenses, 70% depending on company size), the recoverable advance (up to €3m and 70% of expenses), repayable unless failure is formally recorded, and the zero-rate innovation loan (PTZI, up to €3m). All reduce the research tax credit base for the expenses funded.

Bpifrance innovation project aid (aide pour projet d'innovation) is public funding granted to a company to carry out a research, development or innovation programme before its industrial or commercial launch. "Aide pour projet d'innovation" remains the common name: Bpifrance's catalogue now splits it into separate product sheets, mainly the Innovation Grant (Subvention Innovation), the Innovation Advance (Avance Innovation), the Innovation Development Aid (Aide pour le développement de l'innovation, a mixed form) and the Zero-Rate Innovation Loan (Prêt à taux zéro pour l'innovation, PTZI).

The Innovation Advance and Innovation Development Aid sheets target SMEs as defined by the EU and mid-sized companies (ETI) with up to 2,000 employees, registered in France. Bpifrance then adjusts its support according to the project's characteristics, its risk level, the company's profile and the genuine incentive effect of the aid.

This article explains how this single scheme works. To place Bpifrance among the other funders (France 2030, the EU, the Regions, tax credits), see our overview of public innovation funding. For a first grant at the ideation stage, look instead at the French Tech Grant conditions.

Source: Bpifrance product catalogue sheets. Ceilings and rates vary from one sheet to another: only the signed agreement is binding. The PTZI sheet also restricts the loan to companies registered in France for more than 3 years and limits it to projects carried out in certain partner regions (Bourgogne-Franche-Comté, Auvergne-Rhône-Alpes, Normandy, Grand Est).

In the Île-de-France region, the Innov'up scheme, co-funded by the Region and Bpifrance, pairs a grant (up to €500,000) with an R&D innovation loan or a recoverable advance (up to €3m), with a support rate of 25% to 70% depending on company size and the nature of the project. Our method for building a regional grant application applies to this type of application.

A project is eligible for Bpifrance innovation project aid when it involves industrial research or experimental development work, carries genuine uncertainty as to its outcome and targets an innovative product, process or service with concrete prospects of industrialisation and commercialisation. The Innovation Advance explicitly targets breakthrough projects or those carrying strong uncertainty as to their success or failure.

Eligible expenses are internal and external costs directly linked to the project. The Innovation Development Aid sheet lists, in particular:

• building and fine-tuning prototypes, pre-series, pilot or demonstration installations;
• intellectual property costs (filing and extending patents, for SMEs only);
• regulatory compliance costs and the design process;
• market test studies and updating the industrialisation and commercialisation business plan.

The PTZI sheet excludes production and marketing expenses, as well as statutory taxes, from the base. One rule applies to every sheet: no expense incurred before the application filing date can be taken into account.

The underestimated risk. The prior-expense rule is easy to comply with, yet costly to forget. A signed purchase order, a dedicated hire or a prototype launched before filing falls outside the base, even if it clearly belongs to the project. File first, commit second, and keep the date of every commitment.

The form of Bpifrance innovation project aid depends first on the project's risk level: the grant suits the most upstream phases, the recoverable advance shares the risk of failure with Bpifrance, and the PTZI assumes a company able to repay whatever the outcome. You do not choose the form alone, but you can discuss the split with your Bpifrance account manager (chargé d'affaires), figures in hand.

Our view. A recoverable advance is not a deferred grant. If the project succeeds, it is repaid on a schedule that includes a discounting factor: the company pays back more than it received. At the firm, we advise modelling the repayments in the financial forecast from signature, success scenario included, rather than reasoning only on the amount granted.

If the project succeeds, a Bpifrance recoverable advance is repaid on a fixed schedule spread over several years and collected quarterly. The instalments include a discount rate equal to the reference and discount rate set by the European Commission on the date of the aid decision, plus 100 basis points.

The advance is paid in two instalments: a first tranche at contract signature, once any conditions precedent are lifted, then the balance on completion of the work, upon submission of an end-of-programme report and a summary statement of expenses paid. Until the balance is paid, the company pre-finances part of the programme: this timing gap must appear in the cash-flow plan.

For France 2030 aid, Bpifrance states that the repayment schedule can be amended on a reasoned request to the project monitoring officer, and that extending the grace period or the repayment term mechanically increases the discounting amount. Read the specific terms (conditions particulières) carefully for the definition of success, the repayment calendar and the financial return conditions provided for.

This discounting has a European rationale. The General Block Exemption Regulation (GBER, Regulation (EU) No 651/2014) allows the maximum aid intensities to be increased by 10 percentage points when the aid takes the form of recoverable advances repaid, in the event of success, at an interest rate at least equal to the discount rate. This is one of the reasons why an advance can cover a larger share of expenses than a grant.

A recoverable advance is not necessarily repaid if the project fails: it carries an obligation of financial return unless Bpifrance formally records the project's failure (constat d'échec), in which case the advance can be waived in whole or in part. The failure finding is a formal decision by the funder, neither an automatic right nor a mere statement by the company.

The situations in which a technical, economic or commercial failure finding can be requested are set out in the contract. For France 2030 projects, Bpifrance specifies that any request must be formalised and reasoned, reviewed by the project monitoring officer and then presented to the funders' governance bodies. More structuring projects often fall under these calls anyway: see how an SME applies to a France 2030 call for projects.

The procedure should be prepared from the project's launch:

1. Reread the failure cases provided for in the contract and the definition of success (technical, commercial, revenue-based).
2. Document the project as it goes: test reports, technical minutes, market studies, governance decisions.
3. Finalise the summary statement of expenses actually incurred on the programme.
4. Send a written, reasoned request to your Bpifrance account manager, without suspending repayments on your own initiative.
5. Wait for the decision, which may grant a total or partial waiver.
6. Reflect the decision in the accounts and the tax return for the financial year in which it is made.

Points to watch. Stopping repayments while awaiting a response turns a technical failure into a payment default. A voluntary halt to the project, a strategic pivot or a lack of resources does not necessarily amount to failure within the meaning of the contract: everything depends on its wording.

For financial years beginning on or after 1 January 2026, a Bpifrance repayable advance is recorded under other equity (autres fonds propres), credited to account 1673 "Conditional advances, principal amount" (Avances conditionnées montant principal), under French accounting standards authority (ANC) Regulation No 2024-07, approved by the order of 26 December 2025. This regulation makes other equity a fully fledged balance sheet heading, made up of non-repayable funds, conditional advances and grantor's rights.

A conditional advance (avance conditionnée) is, under the French general chart of accounts (plan comptable général), an advance granted by the State, a public body or an entity they control, whose repayment depends on the success of the funded project and which the lender waives in whole or in part if the project fails. The entry in account 1673 is kept until the principal is fully repaid or until the lender waives the debt. Accrued interest goes to account 1674 "Conditional advances, accrued interest" when its payment, like the principal, depends on the project's success and is waived if the project fails; interest that is not conditional is recorded as a debt. The regulation applies to financial years beginning on or after 1 January 2026, with early application permitted.

If the grant funds expenses recorded as assets, for example capitalised development costs, the question of classifying it as an investment grant arises: see our article on accounting for and spreading investment grants.

Waiving an advance is not automatically exceptional income. Since the reform of financial statements applicable to financial years beginning on or after 1 January 2025 (ANC Regulation No 2022-06), exceptional items are limited to income and expenses directly linked to a major and unusual event.

Our view. The failure of an R&D project is a risk inherent in innovation, not an unusual event for a company that innovates. Barring particular circumstances, the firm favours classifying the waiver within ordinary profit, with a description in the notes. This choice is documented at year-end, backed by the contract and Bpifrance's decision.

For a company with a 31 December year-end, the 2026 accounts are the first ones affected: the presentation of advances in progress must be reviewed under the regulation's first-time application rules. This agreement-by-agreement monitoring is part of our bookkeeping and accounts review engagement.

A Bpifrance repayable advance is not taxable when received: as long as it qualifies as a simple advance, the amount received is offset by a debt and does not affect taxable profit, according to French tax guidance BOI-BIC-PDSTK-10-30-10-10. Its repayment likewise has no impact on taxable income.

The waiver, however, is taxable. When the company is granted a remission of all or part of the advances, the corresponding amounts become vested receivables and are allocated to the results of the financial year in progress on the date of that remission. What matters is therefore the date of Bpifrance's decision, not the date the work stopped.

A failure can thus generate taxable profit in the year the company is doing worst. Tax losses carried forward can absorb all or part of this income, within the limits of the carry-forward rules: the simulation should be done before year-end, not after. The operating grant, for its part, is taxable in the financial year in which it is earned.

Bpifrance innovation project aid can be combined with the research tax credit (crédit d'impôt recherche, CIR), but it reduces its base: Article 244 quater B of the French General Tax Code (CGI) requires public grants received for eligible operations to be deducted from the calculation base, whether they are definitively vested or repayable. The deduction applies in the year in which the expenses funded by the aid are incurred.

When the advance is repaid, the amounts repaid are added to the CIR base for the year of repayment. French tax guidance (BOFiP) specifies that zero-rate innovation loans distributed by Bpifrance follow the same rules as repayable grants. If the project fails and the advance is waived, nothing is repaid, so nothing is added back: the deduction becomes final.

Only the portion of the aid allocated to CIR-eligible expenses is deducted: a market test funded by Bpifrance does not necessarily fall within the CIR. The detailed calculation is set out in our article on deducting grants from the CIR base. The same Article 244 quater B governs the innovation tax credit (CII) for SMEs: aid that funds a prototype also reduces the CII base.

On the State aid side, the agreement states the legal basis used: either an exempted scheme under the GBER (in France, framework scheme SA.111723 covers research, development and innovation aid for the 2024-2026 period), or the de minimis Regulation (EU) 2023/2831, which caps such aid at €300,000 per single undertaking over three years. The GBER allows aid covering the same costs to be combined as long as the combination does not exceed the applicable maximum intensity. Young innovative company status (jeune entreprise innovante, JEI) does not prevent Bpifrance aid: it simply makes a tracking table of all aid received indispensable.

Points to watch in 2026. Three dates matter this year. Conditional advances move to other equity for financial years beginning on or after 1 January 2026. Member States have been recording de minimis aid in a publicly accessible central register since 1 January 2026. The SA.111723 R&D&I framework scheme expires on 31 December 2026, which may change the legal basis cited in agreements signed afterwards.

Take an illustrative example. An SME commits to a programme of €600,000 of expenses, all assumed to be CIR-eligible for clarity. Bpifrance grants mixed aid of €270,000, i.e. 45%: a €90,000 grant and a €180,000 recoverable advance.

In practice. At the firm, we advise keeping a single file for each Bpifrance agreement that links three readings of the same funding: the balance sheet (account 1673 or borrowing), the profit and loss (grant, waiver) and the CIR (deduction, add-back). This annual reconciliation avoids the two costly mistakes: forgetting to deduct the aid, or forgetting to add back the repaid advance.

• File the application before committing any programme expense
• Identify in the agreement the form of each portion (grant, advance, loan) and the legal basis (GBER or de minimis)
• Reread the definition of success, the failure cases and the repayment calendar
• Include the discounted instalments in the cash-flow forecast, success scenario included
• Open a tracking file per agreement: payments received, expenses substantiated, repayments, project status
• Deduct the aid from the CIR or CII base in the year of the expenses, then add back repayments
• Present the advance in account 1673 from the financial year beginning in 2026
• Document the project technically from the outset, in anticipation of a possible failure finding

• Bpifrance innovation project aid combines, depending on the project, a grant, a recoverable advance (up to €3m) and a PTZI (up to €3m).
• The advance is repaid with discounting if the project succeeds; it can be waived in whole or in part after a formal failure finding.
• For financial years beginning on or after 1 January 2026, the advance is recorded under other equity, in account 1673.
• The waiver is taxable in the year of Bpifrance's decision and is not automatically exceptional income.
• Any aid, vested or repayable, is deducted from the CIR base; the repaid advance is added back in the year of repayment.

Informational content reviewed by a chartered accountant registered with the Ordre des experts-comptables d'Île-de-France. The decision depends on your agreement, your accounts and the law applicable on the date of the transaction.